NO20014012L - Inhibitorer for anvendelse i hemostase og immunfunksjon - Google Patents

Inhibitorer for anvendelse i hemostase og immunfunksjon

Info

Publication number
NO20014012L
NO20014012L NO20014012A NO20014012A NO20014012L NO 20014012 L NO20014012 L NO 20014012L NO 20014012 A NO20014012 A NO 20014012A NO 20014012 A NO20014012 A NO 20014012A NO 20014012 L NO20014012 L NO 20014012L
Authority
NO
Norway
Prior art keywords
hemostasis
inhibitors
immune function
related protein
complement related
Prior art date
Application number
NO20014012A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014012D0 (no
Inventor
Paul O Sheppard
Gerald W Lasser
Paul D Bishop
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of NO20014012D0 publication Critical patent/NO20014012D0/no
Publication of NO20014012L publication Critical patent/NO20014012L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20014012A 1999-02-19 2001-08-17 Inhibitorer for anvendelse i hemostase og immunfunksjon NO20014012L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25360499A 1999-02-19 1999-02-19
US44479499A 1999-11-22 1999-11-22
PCT/US2000/004161 WO2000048625A2 (fr) 1999-02-19 2000-02-17 Inhibiteurs utilises dans l'hemostase et la fonction immunitaire

Publications (2)

Publication Number Publication Date
NO20014012D0 NO20014012D0 (no) 2001-08-17
NO20014012L true NO20014012L (no) 2001-10-02

Family

ID=26943406

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014012A NO20014012L (no) 1999-02-19 2001-08-17 Inhibitorer for anvendelse i hemostase og immunfunksjon

Country Status (20)

Country Link
US (1) US6448221B1 (fr)
EP (2) EP1154785B1 (fr)
JP (1) JP2002537270A (fr)
KR (1) KR20010102130A (fr)
CN (1) CN1341027A (fr)
AT (1) ATE245439T1 (fr)
AU (1) AU772103B2 (fr)
BR (1) BR0008298A (fr)
CA (1) CA2361273A1 (fr)
CZ (1) CZ20012916A3 (fr)
DE (1) DE60004015T2 (fr)
DK (1) DK1154785T3 (fr)
ES (1) ES2202061T3 (fr)
HK (1) HK1039892A1 (fr)
HU (1) HUP0105284A3 (fr)
IL (1) IL144460A0 (fr)
NO (1) NO20014012L (fr)
PL (1) PL349924A1 (fr)
PT (1) PT1154785E (fr)
WO (1) WO2000048625A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525174B1 (en) 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
US20040014650A1 (en) * 2002-07-17 2004-01-22 Sheppard Paul D Methods for enhancing wound repair
US6544946B1 (en) * 1999-02-19 2003-04-08 Zymogenetics, Inc. Inhibitors for use in hemostasis and immune function
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
MY128992A (en) * 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen
CA2424029C (fr) 2000-09-29 2008-01-29 Cordis Corporation Dispositifs medicaux enrobes
US20030220253A1 (en) * 2002-03-08 2003-11-27 Lasser Gerald W. Inhibitors for use in hemostasis
NO20035748D0 (no) * 2003-12-19 2003-12-19 Amersham Health As Optisk avbildning av sårbar arteriosklerose
RU2279853C2 (ru) * 2004-07-23 2006-07-20 Наталья Юрьевна Демидова Способ коррекции нарушений гемостаза при обширных операциях на органах гепатопанкреатодуоденальной зоны
US9471978B2 (en) 2004-10-04 2016-10-18 Banner Health Methodologies linking patterns from multi-modality datasets
US7964557B2 (en) * 2005-03-28 2011-06-21 University Of Louisville Research Foundation, Inc. Inhibition of wet type age related macular degeneration (AMD) by adiponectin or acrp 30
CA2616912A1 (fr) * 2005-07-29 2007-02-08 Laboratoires Serono S.A. Utilisation d'acrp30 pour le traitement et/ou la prevention de la thrombose et du cancer
US8686117B2 (en) 2006-12-21 2014-04-01 Jnc Corporation Platelet aggregation inducing substance
JP5747370B2 (ja) * 2009-03-31 2015-07-15 国立大学法人浜松医科大学 高病原性口腔細菌の高感度検出法
WO2023215294A1 (fr) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la voie du complément à des fins de cicatrisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869330A (en) * 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
EP1000084A4 (fr) 1997-07-08 2003-03-26 Human Genome Sciences Inc 123 proteines humaines secretees
HUP0003762A3 (en) * 1997-07-18 2005-11-28 Zymogenetics Inc Adipocyte-specific protein homologs
DK1000149T3 (da) 1997-08-01 2007-09-10 Serono Genetics Inst Sa 5'-EST'ere til udskilte proteiner identificeret fra hjernevæv
WO1999010492A1 (fr) 1997-08-26 1999-03-04 Zymogenetics, Inc. Homologues de proteines specifiques aux adipocytes
JP3538711B2 (ja) 1997-10-29 2004-06-14 大塚製薬株式会社 平滑筋増殖抑制組成物、動脈硬化症診断方法及びそのキット
NZ527900A (en) 1997-12-03 2005-02-25 Genentech Inc PRO361 polypeptides and nucleic acids with homology to mucin and chitinase
WO1999033979A2 (fr) 1997-12-30 1999-07-08 Chiron Corporation Proteines secretees par la moelle osseuse et polynucleotides
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
WO1999055865A1 (fr) 1998-04-29 1999-11-04 Genesis Research And Development Corporation Limited Polynucleotides isoles de cellules de la peau et leurs procedes d'utilisation
EP1085897A4 (fr) 1998-05-21 2003-03-12 Smithkline Beecham Corp Acrp30r1l, homologue de acrp30 (proteine associee a un complement de l'adipocyte 30 kd)

Also Published As

Publication number Publication date
KR20010102130A (ko) 2001-11-15
ATE245439T1 (de) 2003-08-15
DK1154785T3 (da) 2003-11-17
EP1154785A2 (fr) 2001-11-21
AU772103B2 (en) 2004-04-08
EP1382345A2 (fr) 2004-01-21
CZ20012916A3 (cs) 2002-05-15
HUP0105284A2 (hu) 2002-05-29
DE60004015T2 (de) 2004-04-15
WO2000048625A3 (fr) 2000-12-28
HK1039892A1 (zh) 2002-05-17
JP2002537270A (ja) 2002-11-05
CN1341027A (zh) 2002-03-20
ES2202061T3 (es) 2004-04-01
PL349924A1 (en) 2002-10-21
WO2000048625A2 (fr) 2000-08-24
AU2883200A (en) 2000-09-04
HUP0105284A3 (en) 2003-12-29
US6448221B1 (en) 2002-09-10
DE60004015D1 (de) 2003-08-28
EP1154785B1 (fr) 2003-07-23
EP1382345A3 (fr) 2004-01-28
NO20014012D0 (no) 2001-08-17
BR0008298A (pt) 2002-02-19
IL144460A0 (en) 2002-05-23
PT1154785E (pt) 2003-12-31
CA2361273A1 (fr) 2000-08-24

Similar Documents

Publication Publication Date Title
NO20014012D0 (no) Inhibitorer for anvendelse i hemostase og immunfunksjon
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
AU5056196A (en) Hydrogel-forming, self-solvating absorbable polyester copolymers and methods for use thereof
ATE483729T1 (de) Peptid
ES2123134T3 (es) Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
CA2181150A1 (fr) Peptides bioroniquement actifs provenant de domaines fonctionnels d'une proteine bactericide augmentant la permeabilite, et leurs utilisations
IS5591A (is) Grunnmassaprótínsamsetningar til sáragræðslu
NO20013608D0 (no) DNA-klon for human vevsfaktorinhibitor
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DE60020681D1 (de) Zusammensetzungen und verfahren zur verbesserung der integrität von angegriffenen körperpassagewegen und höhlen
ITTO20010804A0 (it) Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
GB9930768D0 (en) Composition
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
NO20021410D0 (no) Forebygging og behandling av blodkoagulasjons-relaterte sykdommer
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE60011601D1 (de) Rekombinantes sp-a zur behandlung und vorbeugung von pulmonaren infektionen und entzündungen
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
ATE439142T1 (de) Kombination von aktiviertem factor viia und fibrinogen und verwendung zur behandlung von blutung
DE50207168D1 (de) Kombinationspräparat zur Therapie von immunologischen Erkrankungen
GEP19991605B (en) Inhibitor, Its Obtaining and Use
UA9703A (uk) Антипротеіназний засіб
UA37445A (uk) Протизапальний засіб
RU94025749A (ru) Способ оперативного лечения дуоденостаза
IT224936Z2 (it) Presidio chirurgico radiotrasparente per il trattamento di patologie e traumi ortopedici.